Last reviewed · How we verify
E2006
At a glance
| Generic name | E2006 |
|---|---|
| Sponsor | Eisai Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Pharmacodynamics of Lemborexant in Korean Participants With Insomnia Disorder (PHASE2)
- A Study to Assess the Pregnancy Outcome in Women Exposed to Dayvigo® During Pregnancy Compared to an Unexposed Control Population
- A Study of Lemborexant in Chinese Participants With Insomnia Disorder (PHASE3)
- Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1) (PHASE3)
- A Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Participants With Moderate to Severe Obstructive Sleep Apnea, and in Adult and Elderly Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (PHASE1)
- A Study to Evaluate the Safety of DAYVIGO (Lemborexant) Tablets in Participants With Insomnia.
- A Study to Evaluate Lemborexant in Milk of Healthy Lactating Women (PHASE1)
- A Single and Multiple Dose Study of Lemborexant in Healthy Chinese Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- E2006 CI brief — competitive landscape report
- E2006 updates RSS · CI watch RSS
- Eisai Inc. portfolio CI